Andreas A Argyriou1, Jordi Bruna2, Garifallia G Anastopoulou3, Roser Velasco2, Pantelis Litsardopoulos1, Haralabos P Kalofonos4. 1. Neurological Department, Saint Andrew's General Hospital of Patras, Patras, Greece. 2. Unit of Neuro-Oncology, Hospital Universitari de Bellvitge-ICO L'Hospitalet-IDIBELL, Barcelona, Spain. 3. Department of Medicine-Oncology Unit, Saint Andrew's General Hospital of Patras, Patras, Greece. 4. Department of Medicine-Division of Oncology, University Hospital, University of Patras Medical School, Rion, 26504, Patras, Greece. kalofonos@upatras.gr.
Abstract
AIM: To identify the risk factors of falls in a well-characterized cohort of cancer patients with chemotherapy-induced peripheral neurotoxicity (CIPN). PATIENTS AND METHODS: We studied 122 cancer patients experiencing any grade of CIPN, following completion of different chemotherapeutic regimens for various non-hematological malignancies. The results of the clinical examination were summarized by means of the Total Neuropathy Score-clinical version (TNSc®). A neurophysiological examination was also carried out. RESULTS: Among 122 patients, 21 (17.2%) of them reported falls. These were 7 males and 14 females with a mean age of 57.3 ± 8.1 years. All of them (21; 100%) had grade 3 CIPN, according to TNSc® with a median value of 15. Univariate analysis showed that the following variables were strongly associated with falls: TNSc® score of > 14 corresponding to grade 3 CIPN, evidence of motor impairment, evidence of sensory ataxia with positive Romberg sign, and decrease of sural a-SAP > 50% from the baseline value. Multivariate regression analysis failed to define independent predictors of falls. However, ROC analysis demonstrated that a discriminative TNSc® cutoff value of > 14 predicted falls with a sensitivity of 100% and specificity of 87%, whereas sensory ataxia predicted falls with a sensitivity of 95% and specificity of 83%. CONCLUSION: Grade 3 CIPN, as assessed with TNSc®, and evidence of sensory ataxia with a positive Romberg sign were strongly associated with an increased risk of falls. Although our results need further validation, the TNSc® scale appears to be a practical and easy tool for identifying patients at higher risk of falling.
AIM: To identify the risk factors of falls in a well-characterized cohort of cancerpatients with chemotherapy-induced peripheral neurotoxicity (CIPN). PATIENTS AND METHODS: We studied 122 cancerpatients experiencing any grade of CIPN, following completion of different chemotherapeutic regimens for various non-hematological malignancies. The results of the clinical examination were summarized by means of the Total Neuropathy Score-clinical version (TNSc®). A neurophysiological examination was also carried out. RESULTS: Among 122 patients, 21 (17.2%) of them reported falls. These were 7 males and 14 females with a mean age of 57.3 ± 8.1 years. All of them (21; 100%) had grade 3 CIPN, according to TNSc® with a median value of 15. Univariate analysis showed that the following variables were strongly associated with falls: TNSc® score of > 14 corresponding to grade 3 CIPN, evidence of motor impairment, evidence of sensory ataxia with positive Romberg sign, and decrease of sural a-SAP > 50% from the baseline value. Multivariate regression analysis failed to define independent predictors of falls. However, ROC analysis demonstrated that a discriminative TNSc® cutoff value of > 14 predicted falls with a sensitivity of 100% and specificity of 87%, whereas sensory ataxia predicted falls with a sensitivity of 95% and specificity of 83%. CONCLUSION: Grade 3 CIPN, as assessed with TNSc®, and evidence of sensory ataxia with a positive Romberg sign were strongly associated with an increased risk of falls. Although our results need further validation, the TNSc® scale appears to be a practical and easy tool for identifying patients at higher risk of falling.
Authors: Marta Seretny; Gillian L Currie; Emily S Sena; Sabrina Ramnarine; Robin Grant; Malcolm R MacLeod; Leslie A Colvin; Marie Fallon Journal: Pain Date: 2014-09-23 Impact factor: 6.961
Authors: Andreas A Argyriou; Guido Cavaletti; Anna Antonacopoulou; Armando A Genazzani; Chiara Briani; Jordi Bruna; Salvatore Terrazzino; Roser Velasco; Paola Alberti; Marta Campagnolo; Sara Lonardi; Diego Cortinovis; Marina Cazzaniga; Cristina Santos; Aikaterini Psaromyalou; Aikaterini Angelopoulou; Haralabos P Kalofonos Journal: Cancer Date: 2013-07-02 Impact factor: 6.860
Authors: A A Argyriou; C Briani; G Cavaletti; J Bruna; P Alberti; R Velasco; S Lonardi; D Cortinovis; M Cazzaniga; M Campagnolo; C Santos; H P Kalofonos Journal: Eur J Neurol Date: 2012-12-17 Impact factor: 6.089
Authors: J S Gewandter; L Fan; A Magnuson; K Mustian; L Peppone; C Heckler; J Hopkins; M Tejani; G R Morrow; S G Mohile Journal: Support Care Cancer Date: 2013-02-28 Impact factor: 3.603
Authors: Andreas A Argyriou; Athanasios P Kyritsis; Thomas Makatsoris; Haralabos P Kalofonos Journal: Cancer Manag Res Date: 2014-03-19 Impact factor: 3.989
Authors: Ting Bao; Raymond Baser; Connie Chen; Matthew Weitzman; Yi Lily Zhang; Christina Seluzicki; Qing Susan Li; Lauren Piulson; W Iris Zhi Journal: Oncologist Date: 2021-08-26
Authors: Ciao-Sin Chen; Judith Kim; Noemi Garg; Harsha Guntupalli; Reshma Jagsi; Jennifer J Griggs; Michael Sabel; Michael P Dorsch; Brian C Callaghan; Daniel L Hertz Journal: JMIR Mhealth Uhealth Date: 2021-07-05 Impact factor: 4.947